RALEIGH, NC--German life sciences company Bayer has signed a contract with Paradigm Genetics here under which they will collaborate in a search for screening targets leading to the development of new herbicides. For contributing its expertise in bioinformatics, gene function identification, and assay development, Paradigm will receive up to $40 million, including milestone payments. Genes identified as being responsible for new targets will be subjected to high-throughput screening.